This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
College can be expensive, but saving money is possible. Learn practical ways to cut costs and keep your finances in check while studying.
27,554 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
As July opens, traders are eyeing a quiet market mover. This unheralded sector sure has a track record of supporting ...
As a new Federal Reserve chair makes his debut, Jim Cramer argues markets should expect stability, not shocks. Trader...
A stock split made shares cheaper, but the real driver of Amazon’s rally is its expanding AI and cloud empire. Here’s...
Trump granted clemency to 11 people on a Friday ahead of July 4, spotlighting emissions-related cases and a partner o...
AI data centers are sparking a sweeping power expansion in the U.S. Three utility ETFs offer distinct routes to ride ...
Analysts warn that the stock market’s double bubble could burst if corporate earnings fail to keep pace with lofty pr...
Tech-led selling pushed the S&P 500 lower on July 7, 2026, as AI demand concerns weigh on sentiment and earnings sign...
A wave of zoning changes could unlock dense housing in cities across the U.S. This article explains how sweeping zoni...
Cardano founder Charles Hoskinson claims Ethereum is lifting Cardano's native UTXO concepts without attribution, spar...
As AI reshapes tech investing, two groups rise: hyperscaler stocks and AI infrastructure stocks. Learn how they inter...
Palo Alto Networks has surged about a month’s worth of gains, fueling a debate on whether to book profits and rotate ...